What to Know About AIDS—and Its Potential Resurgence Amid U.S. Foreign-Aid Freeze
HIV is spread by bodily fluids such as blood, breast milk or semen. It gradually weakens the body’s immune system and makes ...
The Nation Newspaper5h
HIV, HPV red flags fly over 2025 Valentine’s Day (1)
Where would you be and what would you be doing tomorrow, February 14 , 2025 Valentine’s Day? Painting the town red or just watching the world go by?My boosts long hung and other Valentine ...
The American Journal of Managed Care14h
Despite Increases, Gender Disparities in Life Expectancy Persist Among People With HIV
An overall increase in life expectancy was observed across all individuals living with HIV but disparities between gender groups persist.
Gilead outlines 2025 sales guidance with lenacapavir launch and HIV focus
Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...
Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised
Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...
Healio1d
Tenofovir-treated HIV associated with increased CKD rate for adults in Tanzania
Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the ...
Biden rule cleared hurdles to lifesaving HIV drug, but in Georgia barriers remain
Preexposure prophylaxis, known as PrEP, reduces the risk of new HIV infections through sex by 99% and among injectable drug ...
Nation4d
What USAID Sh1trn to Kenya funded in 24 years and huge gap after Donald Trump shocker
Between 2001 and 2024, USD 9.74 billion (Sh1.25 trillion) has been disbursed to Kenya through USAID which represents 68.33 ...
Chattanooga Times Free Press4d
Georgia leads in U.S. HIV cases. Here’s why the lifesaving drug PrEP faces barriers in the state.
This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.
Fierce Pharma6d
Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...